vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and GENCOR INDUSTRIES INC (GENC). Click either name above to swap in a different company.
GENCOR INDUSTRIES INC is the larger business by last-quarter revenue ($23.6M vs $15.0M, roughly 1.6× CHAMPIONS ONCOLOGY, INC.). GENCOR INDUSTRIES INC runs the higher net margin — 14.6% vs 1.8%, a 12.8% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -25.0%). GENCOR INDUSTRIES INC produced more free cash flow last quarter ($10.1M vs $-2.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -23.9%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Gencor Industries Inc is a leading manufacturer of heavy construction and infrastructure equipment, specializing in asphalt production plants, thermal combustion systems, and supporting road-building machinery. It primarily serves North American and global construction markets, supplying products to both public sector infrastructure projects and private commercial construction operators.
CSBR vs GENC — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $23.6M |
| Net Profit | $268.0K | $3.4M |
| Gross Margin | 51.7% | 28.7% |
| Operating Margin | 1.2% | 13.2% |
| Net Margin | 1.8% | 14.6% |
| Revenue YoY | 11.5% | -25.0% |
| Net Profit YoY | -63.2% | -9.8% |
| EPS (diluted) | $0.02 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $23.6M | ||
| Q3 25 | $14.0M | $18.8M | ||
| Q2 25 | $12.4M | $27.0M | ||
| Q1 25 | $17.0M | $38.2M | ||
| Q4 24 | $13.5M | $31.4M | ||
| Q3 24 | $14.1M | $20.9M | ||
| Q2 24 | $14.0M | $25.6M | ||
| Q1 24 | $12.0M | $40.7M |
| Q4 25 | $268.0K | $3.4M | ||
| Q3 25 | $-436.0K | $1.9M | ||
| Q2 25 | $-1.8M | $3.8M | ||
| Q1 25 | $4.5M | $6.1M | ||
| Q4 24 | $728.0K | $3.8M | ||
| Q3 24 | $1.3M | $1.5M | ||
| Q2 24 | $-109.0K | $2.6M | ||
| Q1 24 | $-2.5M | $6.2M |
| Q4 25 | 51.7% | 28.7% | ||
| Q3 25 | 42.9% | 24.2% | ||
| Q2 25 | 41.1% | 26.5% | ||
| Q1 25 | 61.2% | 29.7% | ||
| Q4 24 | 44.9% | 27.6% | ||
| Q3 24 | 49.7% | 25.6% | ||
| Q2 24 | 48.2% | 23.9% | ||
| Q1 24 | 34.7% | 30.3% |
| Q4 25 | 1.2% | 13.2% | ||
| Q3 25 | -3.8% | -1.2% | ||
| Q2 25 | -16.2% | 11.6% | ||
| Q1 25 | 26.4% | 17.0% | ||
| Q4 24 | 5.4% | 14.7% | ||
| Q3 24 | 9.5% | 5.9% | ||
| Q2 24 | -1.9% | 7.8% | ||
| Q1 24 | -21.4% | 17.4% |
| Q4 25 | 1.8% | 14.6% | ||
| Q3 25 | -3.1% | 10.2% | ||
| Q2 25 | -14.9% | 14.2% | ||
| Q1 25 | 26.4% | 16.0% | ||
| Q4 24 | 5.4% | 12.1% | ||
| Q3 24 | 9.3% | 6.9% | ||
| Q2 24 | -0.8% | 10.0% | ||
| Q1 24 | -21.1% | 15.3% |
| Q4 25 | $0.02 | $0.23 | ||
| Q3 25 | $-0.03 | $0.13 | ||
| Q2 25 | $-0.12 | $0.26 | ||
| Q1 25 | $0.31 | $0.42 | ||
| Q4 24 | $0.05 | $0.26 | ||
| Q3 24 | $0.09 | $0.10 | ||
| Q2 24 | $-0.01 | $0.17 | ||
| Q1 24 | $-0.19 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $147.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $215.2M |
| Total Assets | $30.2M | $228.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $147.7M | ||
| Q3 25 | $10.3M | $136.3M | ||
| Q2 25 | $9.8M | $136.0M | ||
| Q1 25 | $3.2M | $143.7M | ||
| Q4 24 | $2.8M | $130.1M | ||
| Q3 24 | $2.9M | $115.4M | ||
| Q2 24 | $2.6M | $116.6M | ||
| Q1 24 | $4.5M | $117.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $4.2M | $215.2M | ||
| Q3 25 | $3.5M | $211.8M | ||
| Q2 25 | $3.8M | $209.9M | ||
| Q1 25 | $5.5M | $206.1M | ||
| Q4 24 | $681.0K | $200.0M | ||
| Q3 24 | $-332.0K | $196.1M | ||
| Q2 24 | $-1.9M | $194.7M | ||
| Q1 24 | $-2.1M | $192.1M |
| Q4 25 | $30.2M | $228.9M | ||
| Q3 25 | $30.5M | $222.6M | ||
| Q2 25 | $32.3M | $220.2M | ||
| Q1 25 | $30.6M | $223.9M | ||
| Q4 24 | $25.2M | $218.2M | ||
| Q3 24 | $24.9M | $208.1M | ||
| Q2 24 | $26.1M | $201.8M | ||
| Q1 24 | $26.8M | $206.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $11.1M |
| Free Cash FlowOCF − Capex | $-2.0M | $10.1M |
| FCF MarginFCF / Revenue | -13.1% | 43.0% |
| Capex IntensityCapex / Revenue | 1.6% | 4.1% |
| Cash ConversionOCF / Net Profit | -6.47× | 3.23× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-3.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $11.1M | ||
| Q3 25 | $600.0K | $-275.0K | ||
| Q2 25 | $6.9M | $-23.9M | ||
| Q1 25 | $490.0K | $12.4M | ||
| Q4 24 | $-283.0K | $14.8M | ||
| Q3 24 | $311.0K | $-3.2M | ||
| Q2 24 | $-1.8M | $-1.0M | ||
| Q1 24 | $-919.0K | $11.7M |
| Q4 25 | $-2.0M | $10.1M | ||
| Q3 25 | $554.0K | $-1.3M | ||
| Q2 25 | $6.6M | $-24.4M | ||
| Q1 25 | $448.0K | $12.3M | ||
| Q4 24 | $-377.0K | $14.5M | ||
| Q3 24 | — | $-3.3M | ||
| Q2 24 | $-1.8M | $-1.4M | ||
| Q1 24 | $-1.0M | $11.7M |
| Q4 25 | -13.1% | 43.0% | ||
| Q3 25 | 4.0% | -6.8% | ||
| Q2 25 | 53.5% | -90.4% | ||
| Q1 25 | 2.6% | 32.2% | ||
| Q4 24 | -2.8% | 46.1% | ||
| Q3 24 | — | -15.8% | ||
| Q2 24 | -13.0% | -5.6% | ||
| Q1 24 | -8.4% | 28.7% |
| Q4 25 | 1.6% | 4.1% | ||
| Q3 25 | 0.3% | 5.4% | ||
| Q2 25 | 2.0% | 1.8% | ||
| Q1 25 | 0.2% | 0.4% | ||
| Q4 24 | 0.7% | 1.0% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 0.0% | 1.5% | ||
| Q1 24 | 0.8% | 0.0% |
| Q4 25 | -6.47× | 3.23× | ||
| Q3 25 | — | -0.14× | ||
| Q2 25 | — | -6.24× | ||
| Q1 25 | 0.11× | 2.04× | ||
| Q4 24 | -0.39× | 3.88× | ||
| Q3 24 | 0.24× | -2.22× | ||
| Q2 24 | — | -0.41× | ||
| Q1 24 | — | 1.87× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
GENC
Segment breakdown not available.
